We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
This document contains a synopsis of causation occurring in psoriasis.
Safety leaflet on topical corticosteroids and withdrawal reactions to help patients and their carers to use these medicines safely.
We are considering making Dovonex Psoriasis 50 microgram/g Ointment available to buy from pharmacies. We always want to involve the public and healthcare professionals in decisions that affect them. We want to know what you think about this change.
The Medicines and Healthcare products Regulatory Agency (MHRA) is advising anyone experiencing skin redness or burning sensations after they have stopped using these creams or ointments to seek advice from their health professional before using these products again.
Reclassification of Dovonex Psoriasis Ointment approved by MHRA
Medicines and Healthcare products Regulatory Agency (MHRA) have today announced the approval of Dovonex Psoriasis 50microgram/g Ointment, which will be available through pharmacies without prescription.
If you suspect exfoliative dermatitis caused by an adverse drug reaction to ustekinumab, stop treatment.
There is an increased risk that some patients may experience psychiatric symptoms with apremilast, including depression and suicidal thoughts. Stop treatment if patients have new psychiatric symptoms or if existing symptoms worsen.
We inform healthcare professionals of new risk minimisation measures for JAK inhibitors used to treat chronic inflammatory disorders, consistent with the measures introduced for tofacitinib (Xeljanz) in 2020 and 2021. This advice affects abrocitinib (Cibinqo▼), baricitinib (Olumiant), upadacitinib (Rinvoq▼), and...
MHRA has found samples of intensive body lotion with aloe vera (OSAS) to contain corticosteroid betamethasone.
A skin cream claiming to be a natural Chinese herbal remedy for treating eczema, contains a potentially harmful steroid and should not be used, warns the Medicines and Healthcare products Regulatory Agency (MHRA).
Check full blood counts before prescribing dimethyl fumarate and then every 6 to 12 months. Stop treatment immediately if you suspect progressive multifocal leukoencephalopathy.
Employment Tribunal decision.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).